the ADBL report

Issue #128, September 2022

An Official Accompaniment to the Alberta Drug Benefit List (ADBL) produced by Alberta Blue Cross

The Expert Committee on Drug Evaluation and Therapeutics (ECDET)

In this issue:

Brief Summary of Drug Review Activities

The Expert Committee on Drug Evaluation and Therapeutics met on July 19, 2022. The Committee reviewed Manufacturer submissions for twenty-five (25) Drug Products for potential listing, or change in listing, on the *ADBL*. The Committee also considered information for a number of supplementary assessments of the coverage status of three (3) Drug Products.

In addition to Drug Products reviewed by the Expert Committee, fifteen (15) Drug Products and Devices underwent Expedited Review for listing on the *ADBL* effective August 1, 2022, and ten (10) Drug Products underwent Expedited Review for listing on the *ADBL* effective September 1, 2022.

The following are highlights of recent changes to the *ADBL* and other topics of general interest. A complete list of changes, as well as the full *ADBL* may be accessed at https://www.ab.bluecross.ca/dbl/publications.php

Highlights of Products Originally Reviewed by the Canadian Agency for Drugs and Technologies in Health (CADTH)

The following Drug Product was reviewed by CADTH and added to the *ADBL* effective July 11, 2022:

- **TRIKAFTA* 50 mg/25 mg/37.5 mg & 75 mg tablets** (elexacaftor / tezacaftor / ivacaftor) (ivacaftor) (VER) via Special Authorization (SA)

A complete list of changes, as well as the full ADBL may be accessed at https://www.ab.bluecross.ca/dbl/publications.php.
Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).*

ABC 81171 (09/2022)

Highlights of Interchangeable (IC) Drug Products Added

Addition of the following Entry IC Drug Product to the *ADBL* has resulted in the creation of New IC Groupings, effective September 1, 2022:

- **BUDESONIDE* 3 mg controlled-release capsule** (budesonide) (TPG) via SA
- **FENTANYL* 50 mcg/mL (100 mcg/2 mL), 50 mcg/mL (250 mcg/5 mL), 50 mcg/mL (1000 mcg/20 mL) & 50 mcg/mL (2500 mcg/50 mL) Injection BP** (fentanyl) (STM) via SA
- **JAMP CALCIUM POLYSTYRENE SULFONATE 999 mg/g oral/rectal powder** (calcium polystyrene sulfonate) (JPC)
- **SANDOZ FESOTERODINE FUMARATE* 4 mg & 8 mg extended-release tablets** (fesoterodine fumarate) (SDZ) via Step Therapy/SA
- **TARO-CALCIPOTRIOL/BETAMETHASONE 50 mcg/0.5 mg/g gel** (calcipotriol monohydrate/betamethasone dipropionate) (TAR)

Highlights of Diabetes Supplies Added

The following device was added to the *ADBL* via Restricted Benefit effective August 1, 2022:

- **MEDISURE EMPOWER BLOOD GLUCOSE TEST STRIPS*** (diabetes supplies) (MDS)

Highlights of Drug Products Added

The following Drug Product was reviewed by the Expert Committee and added to the *ADBL* effective August 1, 2022:

- **HALYCIL 50 mg tablet** (propylthiouracil) (ACI)

The following Drug Products were reviewed by the Expert Committee and added to the *ADBL* effective September 1, 2022:

- **DEPO-PROVERA 150 mg/mL prefilled syringe** (medroxyprogesterone acetate) (PFI)
- **DUPIXENT* 300 mg injection pen** (dupilumab) (SAV) via SA
- **SKYRIZI* 150 mg/mL injection pen & injection syringe** (risankizumab) (ABV) via SA

Special Authorization Criteria Changes

The Special Authorization criteria for coverage for the following Drug Product have been revised effective July 11, 2022:

- **TRIKAFTA* 100 mg/50 mg/75 mg & 150 mg tablets** (elexacaftor / tezacaftor / ivacaftor) (ivacaftor) (VER)

A complete list of changes, as well as the full ADBL may be accessed at https://www.ab.bluecross.ca/dbl/publications.html.

Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).*

ABC 81171 (09/2022)